Ciprofloxacin

Bactericidal by inhibition of DNA supercoiling in the bacteria. One of the most active fluroquinolones, it’s spectrum includes gram – negative aerobic bacteria including Enterobacteriaceae, Haemophilus, Neisseriae and Pseudomonas aeruginosa. It is also active in vitro, against many Gram positive aerobic pathogens including penicilinase-producing, and methicillin-resistant staphylococci.

Indications & Dosage:

Oral – UTI:250-500 mg b.i.d.
Prostatitis and complicated UTI: 500 mg 12 hourly
Lower Respiratory & Tract Infections : 250-500 mg , 12 hourly.Sometimes 750 mg 12 hourly may be given.
Skin & soft Tissue, Bone and Joint Infections: 500-750 mg 12 hourly.
Surgical Prophyaxis – 750mg 60-90 mins before procedure.

IV : UTI: 100 mg by slow infusion. Gonorrhoea : 100 mg single dose.
Renal Impairment : Dose changes according to creatinine clearance. Duration of treatment: Generally 5-7 days. Continued for atleast 3 days after symptoms have subsided.

Composition:

Each Tablet Contains

(a) Ciprofloxacin B.P. 250mg.

(b) Ciprofloxacin B.P. 500mg.

Safety Alert:

CL: Children below 12 years and adolescents except where benefit clear exceeds risk. Pregnancy, Lactation, Risk.
SP: Epilepsy, severe renal dysfunction, history of convulsive disorders.
INT POT-HAZ : Decreased ciprofloxacin absorption when co=administered with magnesium-aluminium antacids.
ADR POT-LT: Anaphylactoid reaction. Others – dizziness, convulsions, headache, confusion.
INT- FOOD: Milk & food reduce rate not extent of absorption. Not clinically signifant.

Cloxacillin

Cloxacillin is resistant to degradation by penicillinases. It is particularly useful against penicillinase– producing staphytococci. Highly active against staph.aureus,strep.pyogenes,strep.viridans and trep.pneumoniae.

Indications & Dosage:

Oral – Skin and soft tissue infections, burns mastitis, osteomyletis, Tonsular Abscess, Pneumonia – 500 mg 6 hrly may be doubled in severe infections. Children 2-10 years Half adult dose.Under 2 years:quarter adult dose. A daily dose of 18 g has been used for acute haematogenous osteitis and Staph infections of CNS.

IM/IV – Severe infections – IM 250-500mg Children – 25-100mg/kg in divided doses.

Composition:

Each Capsule Contains

(a) Cloxacillin B.P. 250mg.

(b) Cloxacillin B.P. 500mg.

Composition(Syrup 30/60ml):

Each 5ml Syrup Contains

Cloxacillin B.P. 125mg.

Safety Alert:

CL:Hypersens to penicillins, jaundice in neonates.

SP: Hepatic disease. Pregnancy & Lactation.

INT POT-HAZ: Loss of potency of cloxacillin in solution reported with erythromycin, gentaicin, kanamycin, colistin sulphomthate sodium, oxytetracycline, chlorpromazine, Vitamin C and polymyxin B sulphate. Cloxacillin should not be added to intravenous lipids, blood products, protein hydrolysates or other proteinaceous fluids(degree of serum protein building for cloxacillin is 94%).Chloramphenicol and tetracycline antagonize bactericidal effect of penicillins. Others – Co-administration of protein binding of cloxacillin thereby increasing free serum levels.

ADR POT-LT: Rare Hypersensivity. Others – Neutropenia, agranulocytosis, neurotoxicity, rash, increased incidence of phlebitis with I.V. administration.

LAB INT: Interferes with urinary test for Bence-Jones proteins.

INT FOOD: Delayed absorption, Lower plasma levels.

Home        R & D        Quality Control        Services        Disclaimer     Contact Us     

Copyright © AshfordLaboratory.com | Design : Ashford Laboratory